+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

(+)-cis-4,5,7a,8,9,10,11,11a-Octahydro-7H-10-methylindolo[1,7-bc][2,6]- naphthyridine: A 5-Ht2C/2B Receptor Antagonist with Low 5-Ht2A Receptor Affinity



(+)-cis-4,5,7a,8,9,10,11,11a-Octahydro-7H-10-methylindolo[1,7-bc][2,6]- naphthyridine: A 5-Ht2C/2B Receptor Antagonist with Low 5-Ht2A Receptor Affinity



Journal of Medicinal Chemistry 38(1): 28-33




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 067194863

Download citation: RISBibTeXText

DOI: 10.1021/jm00001a007


Related references

(+)-cis-4,5,7a,8,9,10,11,11a-octahydro-7H-10-methylindolo[1,7- bc][2,6]-naphthyridine: a 5-HT2C/2B receptor antagonist with low 5-HT2A receptor affinity. Journal of Medicinal Chemistry 38(1): 28-33, 1995

Is the apparent antipsychotic action of the 5-HT2A receptor antagonist M100907 counteracted by concomitant 5-HT2C receptor antagonist treatment?. Society for Neuroscience Abstracts 24(1-2): 1369, 1998

Effects of the 5-HT2A receptor antagonist, MDL 100,907 and the 5-HT2C receptor antagonist, SB 206553, on lordosis responding of female rats. Society for Neuroscience Abstracts 24(1-2): 1924, 1998

The effects of antipsychotics with 5-HT2C receptor affinity in behavioral assays selective for 5-HT2C receptor antagonist properties of compounds. European Journal of Pharmacology 388(1): 57-67, Jan 24, 2000

5-HT2c receptor antagonists, but not a 5-HT2A or 5-HT2B receptor antagonist, attenuate haloperidol-induced catalepsy in rat. British Journal of Pharmacology 125(PROC SUPPL ): 65P, 1998

Effects of the 5-HT2C receptor agonist Ro60-0175 and the 5-HT2A receptor antagonist M100907 on nicotine self-administration and reinstatement. Neuropharmacology 62(7): 2288-2298, 2012

Effects of the serotonin 5-HT2A/2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat. European Journal of Pharmacology 553(1-3): 163-170, 2006

(1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity. European Journal of Pharmacology 615(1-3): 1-9, 2009

Differential effects of the 5-HT2A receptor antagonist MDL100,907 and the 5-HT2C receptor antagonist SB242,084 on cocaine induced locomotor activity, cocaine self-administration and cocaine induced reinstatement of responding. Society for Neuroscience Abstracts 27(1): 1176, 2001

Functional characteristics of serotonin 5-HT2A and 5-HT2C receptors in the brain and the expression of the 5-HT2A and 5-HT2C receptor genes in aggressive and non-aggressive rats. Neuroscience and Behavioral Physiology 40(4): 357-361, 2010

Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling. Life Sciences 73(2): 193-207, May 30, 2003

Anxiety-related behaviours on the unstable elevated exposed plus maze are enhanced by meta-chlorophenylpiperazine, a 5-HT2C/2B receptor agonist, and inhibited by SB 242084, a selective 5-HT2C receptor antagonist. Society for Neuroscience Abstracts 26(1-2): Abstract No -659 7, 2000

R-fluoxetine has affinity for 5-HT2A and 5-HT2C receptor subtypes as well as 5-HT uptake sites and increases extracellular levels of serotonin, dopamine and norepinephrine in rat prefrontal cortex. Society for Neuroscience Abstracts 26(1-2): Abstract No -684 5, 2000

Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor. Journal of Pharmacological Sciences 102(2): 189-195, 2006

Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. Journal of Pharmacology and Experimental Therapeutics 339(1): 99-105, 2011